TheraRadar

Genexine

Pre-Approval PRO BETA
🟡

Slowing Activity

No new clinical trials started in 1-2 years. Monitor for changes in pipeline strategy. Last trial started: 10/29/2024

27
Total Trials
2
Phase 3
11
Phase 2
1
Recruiting
181
Score

Pipeline by Phase

Phase 3
2
Phase 2
11
Phase 1
21

Therapeutic Focus

Healthy SARS-CoV-2 Newly Diagnosed Glioblastoma Head and Neck Cancer Cervical Cancer

Clinical Trials (27)

NCT06466785 Phase 3 RECRUITING

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Started: 1/25/2024

NCT05067946 Phase 2 WITHDRAWN

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

Started: 10/1/2021

NCT03309891 Phase 2 COMPLETED

Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency

Started: 1/18/2016

NCT02044653 Phase 2 COMPLETED

Study to Evaluate the Efficacy and Safety of GX-E2 in the Anemic Patients Diagnosed With Chronic Kidney Disease (CKD)

Started: 4/15/2014

NCT02946606 Phase 2 COMPLETED

A Clinical Study in AGHD to Assess Safety, Tolerability and Efficacy of GX-H9

Started: 1/1/2015

NCT02139267 Phase 2 COMPLETED

Dose-finding, Safety Study of Plasmid DNA Therapeutic Vaccine to Treat Cervical Intraepithelial Neoplasia

Started: 7/1/2014

NCT02079324 Phase 1 COMPLETED

Genetically Modified Mesenchymal Stem Cell Theraopeutic Against Head and Neck Cancer

Started: 3/1/2014

NCT06490939 Phase 1 COMPLETED

Clinical Trial of Efepoetin Alfa in Healthy Subjects

Started: 10/29/2024

NCT04715997 Phase 1 COMPLETED

Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Started: 12/30/2020

NCT04445389 Phase 1 TERMINATED

Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Started: 6/17/2020

NCT03444376 Phase 1 COMPLETED

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Started: 6/19/2018

NCT03752723 Phase 1 COMPLETED

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Started: 3/27/2019

NCT04915989 Phase 1 COMPLETED

Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

Started: 2/16/2021

NCT04730427 Phase 1 TERMINATED

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

Started: 3/24/2021

NCT04065087 Phase 1 WITHDRAWN

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Started: 8/22/2019

NCT04298749 Phase 1 COMPLETED

Safety and Tolerability of GX-P1 in Healthy Male Volunteers

Started: 8/11/2020

NCT03619239 Phase 1 COMPLETED

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Started: 6/20/2018

NCT03276988 Phase 1 COMPLETED

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Started: 9/7/2017

NCT03733587 Phase 1 COMPLETED

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Started: 10/17/2018

NCT03478995 Phase 1 COMPLETED

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Started: 3/5/2018

NCT03144934 Phase 1 COMPLETED

Safety and Tolerability of GX-I7 in HPV-infected Female Volunteers

Started: 2/16/2017

NCT02860715 Phase 1 COMPLETED

Clinical Trial of GX-I7 in Healthy Volunteers

Started: 7/11/2016

NCT03651466 Phase 1 COMPLETED

Safety and Tolerability of GX-G6 in Healthy Male Subjects

Started: 8/31/2017

NCT01951027 Phase 1 COMPLETED

Phase I Study GX-G3 in Healthy Subjects

Started: 9/1/2013

NCT02291991 Phase 1 COMPLETED

Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GX-E2 in Healthy Subjects

Started: 11/1/2014

NCT01634503 Phase 1 COMPLETED

Safety of GX-188E DNA Therapeutic Vaccine Administered by Electroporation to Cervical Intraepithelial Neoplasia Grade 3

Started: 11/1/2012

NCT01641536 Phase 1 COMPLETED

Tolerability, Immunogenicity and Efficacy of HB-110 Administered by Electroporation in Chronic Hepatitis B Patients

Started: 11/1/2011

Drug Candidates

GX-051 Efepoetin Alfa GX-19N Placebo GX-19 Saline GX-188E KEYTRUDA® Darbepoetin Alfa GX-I7
Activity Status: Slowing
Last Trial Started: 10/29/2024
Last Trial Ended: 3/25/2025
Trials (12 months): 0
Completed Trials: 22
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.